MARINUS ANTONIUS JACOBUS
HERMSEN
Investigador/a en el periodo 2004-2018
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (1)
2022
-
BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
European Journal of Cancer, Vol. 174, pp. S9-S10